Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells

Te Chun Hsia, Chih Yen Tu, Yun Ju Chen, Ya Ling Wei, Meng Chieh Yu, Sheng Chie Hsu, Shing Ling Tsai, Wen Shu Chen, Ming Hsin Yeh, Chia Jui Yen, Yung Luen Yu, Tzung Chi Huang, Chih Yang Huang, Mien Chie Hung, Wei Chien Huang

研究成果: Article同行評審

35 引文 斯高帕斯(Scopus)

摘要

Lapatinib, a dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) kinase inhibitor, showed clinical benefits in advanced HER2-positive breast cancer patients. Because some triple-negative breast cancers (TNBCs) frequently overexpress EGFR, the antitumor activity of lapatinib in such diseases was also tested. However, the results showed a worse event-free survival rate. It remains unknown whether and how lapatinib elicits the aggressiveness of such cancer cells. In this study, our results demonstrated that lapatinib facilitated axillary and lung metastases of triple-negative MDA-MB-231 breast cancer cells without affecting their viability, leading to worse survival in orthotopic xenograft mice. The lapatinib-increased motility was attributed by the elevation of EGFR through the downregulation of microRNA-7 and by the subsequent overexpression of cyclooxygenase-2 (COX-2). Strikingly, independent of its kinase activity, the elevated EGFR at least partly stabilized COX-2 expression by enhancing the binding of HuR to COX-2 mRNA. Our results suggest that lapatinib may increase the migration and invasion of MDA-MB-231 cells by upregulating EGFR and COX-2 through the downregulation of microRNA-7, providing a potential explanation for the worse clinical outcome of TNBC patients who receive lapatinib-based treatment. These findings also shed new light on the molecular mechanism of COX-2 mRNA stabilization by EGFR in a kinase-independent manner.

原文English
頁(從 - 到)857-869
頁數13
期刊Molecular Pharmacology
83
發行號4
DOIs
出版狀態Published - 2013 4月

All Science Journal Classification (ASJC) codes

  • 分子醫學
  • 藥理

指紋

深入研究「Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells」主題。共同形成了獨特的指紋。

引用此